GlassScriptPhysician profile
Nueki Naate
NPI 1528588928
$9,594.64
in general payments reported to CMS, 2019-2025
40 companies · $2,924 in 2025
The $2,924 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $235 · 2021: $1,491 · 2022: $914 · 2023: $1,617 · 2024: $2,413 · 2025: $2,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,904 · Education: $50.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,904.37 |
| Education | $50.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,219.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,444.46 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,074.02 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $965.35 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $616.32 | 2023-2025 | |
| Amgen INC. | $330.17 | 2021-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $252.72 | 2023-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $251.22 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.23 | 2023-2025 | Caplyta |
| Amarin Pharma, INC. | $223.79 | 2020-2021 | |
| Lundbeck LLC | $182.01 | 2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $167.34 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $163.33 | 2021-2024 | |
| Axsome Therapeutics, INC. | $161.37 | 2024-2025 | Auvelity, Symbravo |
| Biohaven Pharmaceuticals, INC. | $138.61 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nueki Naate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.